Raymond James & Associates Collegium Pharmaceutical, Inc Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding COLL
# of Institutions
256Shares Held
38.6MCall Options Held
100KPut Options Held
21.1K-
Black Rock Inc. New York, NY5.79MShares$178 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.64MShares$80.9 Million1.79% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.59MShares$79.5 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.35MShares$72.1 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.75MShares$53.6 Million0.04% of portfolio
About COLLEGIUM PHARMACEUTICAL, INC
- Ticker COLL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 34,126,200
- Market Cap $1.05B
- Description
- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...